Abstract
Systemic sclerosis (SSc) is a connective tissue disorder with an unknown etiology. There are currently no effective therapies for SSc. (In this study, working with a bleomycin(BLM)-induced scleroderma model mice, we performed two transfections of human hepatocyte growth factor (HGF) cDNA into the skeletal muscle and showed that this treatment not only helped to prevent the dermal sclerosis simultaneously injected BLM but also improved the symptoms of dermal sclerosis induced by BLM 4 weeks previously.) RT-PCR, ELISA and an immunohistochemical analysis revealed that both mRNA and protein of human HGF as well as murine HGF were enhanced in the skin, lung, muscle and the serum after two transfections of human HGF cDNA. These analyses also revealed that this treatment significantly reduced both the expression of the TGF-β1 mRNA and the production of TGF-β1 on macrophage-like cells that infiltrated the dermis and the fibroblastic cells in BLM-induced scleroderma. Furthermore, HGF-gene transfection both prevented and ameliorated the symptoms of not only dermal sclerosis but also of lung fibrosis induced by a subcutaneous BLM injection. These results indicated that gene therapy by the transfection of the human HGF cDNA may thus be a useful therapy for SSc and lung fibrosis involved with SSc.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Krieg T, Meurer M . Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 1988; 18: 457–481.
LeRoy EC . A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 1992; 51: 286–288.
Jimenez SA, Christner P . Animal models of systemic sclerosis. Clin Dermatol 1994; 12: 425–436.
Umezawa H, Maeda K, Takeuchi T, Okami Y . New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 1996; 19: 200–209.
Cohen IS et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 1973; 107: 553–555.
Finch WR et al. Bleomycin-induced scleroderma. J Rheumatol 1980; 7: 651–659.
Nixon DW, Pirozzi D, York RM . Dermatologic changes after systemic cancer therapy. Cutis 1981; 27: 181–194.
Yamamoto T, Yokozeki H, Nishioka K . Dermal sclerosis in the lesional skin of ‘flagellate’ erythema (scratch dermatitis) induced by bleomycin. Dermatology 1998; 197: 399–400.
Adamson IVR, Bowden DH . The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974; 77: 185–198.
Chandler DB . Possible mechanisms of bleomycin-induced pulmonary fibrosis in mice. Clin Chest Med 1990; 11: 21–30.
Yamamoto T et al. Animal model of sclerotic skin. I. Repeated injections of bleomycin induce dermal sclerosis mimicking scleroderma. J Invest Dermatol 1999; 112: 456–462.
Yamamoto T et al. Animal model of sclerotic skin. II. Bleomycin-induced scleroderma in genetically mast cell deficient WBB6F1-W/WV mice. J Rheumatol 1999; 26: 2628–2634.
Yamamoto T, Takagawa S, Kuroda M, Nishioka K . Effect of interferon-γ on experimental scleroderma induced by bleomycin. Arch Dermatol Res 2000; 292: 362–365.
Yamamoto T, Takagawa S, Katayama I, Nishioka K . Anti-sclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-indued scleroderma. Clin Immunol 1999; 92: 6–13.
Nakamura T, Nawa K, Ichihara A . Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122: 1450–1459.
Nakamura T . Molecular cloning and expression of human hepatocytes growth factor. Nature 1989; 342: 440–443.
Kawada K, Matsumoto K, Shimuzu H, Nakamura T . Hepatocyte growth factor prevents acute renal failure and accelerates renal regulation in mice. Proc Natl Acad Sci USA 1994; 91: 4357–4361.
Ohmichi H, Matsumoto K, Nakamura T . In vivo mitogenic action of HGF on lung epithelial cells: pulmotrophic roles in lung regeneration. Am J Physiol 1996; 14: L1031–L1039.
Kato Y, Yu D, Lukish JR, Schwart MZ . Influence of luminar hepatocyte growth factor on small intestine mucosa in vivo. J Surg Res 1997; 71: 49–53.
Bardelli A . HGF receptor associates with anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996; 15: 6205–6212.
Kmiecik TE, Keller JR, Rosen E, Vande Woude GF . Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood 1992; 80: 2454–2457.
Matsuda Y, Matsumoto K, Ichida T, Nakamura T . Hepatocyte growth factor prevents liver cirrhosis caused by dimethylnitrosamine in rats. J Biochem 1995; 118: 643–649.
Saeki Y et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Human Gene Therapy 1997; 20: 2133–2141.
Ueki T et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226–230.
Hayashi S-I et al. Autocrine–paracrine effects of overexpression of hepatocyte growth factor gene on growth of endothelial cells. Biochem Biophys Res Commun 1996; 220: 539–545.
Mizuno S, Matsumoto K, Kurosawa T, Okamoto M . Reciprocal balance of hepatocyte growth factor and transforming growth factor-β1 in renal fibrosis in mice. Kidney Int 2000; 57: 937–948.
Mizuno S et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 1998; 101: 1827–1834.
Yasuda HE et al. Antifibrogenesis effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 1996; 24: 636–642.
Uehara Y et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995; 373: 702–705.
Matsumoto K, Kagoshima M, Nakamura T . Hepatocyte growth factor as a potent survival factor for rat pheochromocytoma PC12 cells. Exp Cell Res 1995; 220: 71–78.
Liu Y, Rajur K, Tolbert E, Dworkin D . Endogeneous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathway. Kidney Int 2000; 58: 2028–2043.
Yaekashiwa M et al. Simultaneous or delayed administration of hepatocyte growth factor represses the fibrotic changes in murine lung injury by bleomycin. Am J Respir Crit Vare Med 1997; 156: 1937–1944.
Tsuboniwa N et al. Safety evaluation of HVJ-AVE liposomes in nonhuman primates. Hum Gene Ther 2001; 12: 469–487.
Isaka Y et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418–423.
Shimaoka S, Imai R, Ogawa H . Dermal papilla cells express hepatocyte growth factor. J Dermatol Sci 1994; 7: s79–s83.
Mizuno S, Matsumoto K, Nakamura T . Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 2001; 59: 1304–1314.
Acknowledgements
This work was partially supported by a grant (Nos. 08670952 and 10670781) from the Ministry of Education and a grant from Scleroderma Research Committee of Ministry of Health and Welfare. We thank Ms Motoko Sekiya for her excellent technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wu, MH., Yokozeki, H., Takagawa, S. et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 11, 170–180 (2004). https://doi.org/10.1038/sj.gt.3302165
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302165
Keywords
This article is cited by
-
Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis
Arthritis Research & Therapy (2022)
-
Antifibrotic therapy by sustained release of low molecular weight heparin from poly(lactic-co-glycolic acid) microparticles on bleomycin-induced pulmonary fibrosis in mice
Scientific Reports (2020)
-
Wenyang Huazhuo Tongluo formula inhibits fibrosis via suppressing Wnt/β-catenin signaling pathway in a Bleomycin-induced systemic sclerosis mouse model
Chinese Medicine (2018)
-
Effect of topical interferon-γ gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk/+ mice
Gene Therapy (2012)
-
Molecular Pathogenesis of Skin Fibrosis: Insight from Animal Models
Current Rheumatology Reports (2010)